Drug
Afimkibart
Afimkibart: highest development phase Phase 3, developed by Roche. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| Afimkibart NCT07298421 | Phase 3 | Moderately to Severely Active Crohns Disease |
| Afimkibart NCT06819878 | Phase 3 | Moderately to Severely Active Crohns Disease |
| Afimkibart NCT06819891 | Phase 3 | Moderately to Severely Active Crohns Disease |
| Afimkibart NCT07846683 | Phase 3 | Moderately to Severely Active Ulcerative Colitis |
Latest
No recent events.
Follow Afimkibart on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.